Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

FMX-8

Fusion protein · developed by FerruMax Pharmaceuticals

Phase 2 Most advanced trial (none active)
1 Registered trials

What is FMX-8?

FMX-8 is a fusion protein of human hemojuvelin (HJV). It is studied in anemia of chronic disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Fusion protein
Therapy area
Hematology
Developer
FerruMax Pharmaceuticals, Inc.
In trials of
DVA
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01873534 Phase 2 Anemia of Chronic Disease Terminated DVA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Anemia of Chronic Disease

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.